Granja-Domínguez, AnabelHochsprung, AnjaLuque-Moreno, CarlosMagni, EleonoraEscudero-Uribe, ShahidHeredia-Camacho, BeatrizIzquierdo-Ayuso, GuillermoHeredia-Rizo, Alberto Marcos2023-05-032023-05-032022-10-13http://hdl.handle.net/10668/22061Multiple sclerosis has a great disability burden. Management of the disease is complex, and patients often seek new conservative approaches. To investigate the effect of low-frequency pulsed electromagnetic field (PEMF) therapy, compared to placebo, on the level of fatigue, walking performance, symptoms of depression, and quality of life (QOL) in patients with relapsing-remitting multiple sclerosis (RRMS). Forty-four adults with RRMS and minimal to significant disability were randomly assigned to a 4-week protocol using a PEMF or a placebo whole-body mat. The PEMF group were initially treated with 15Hz frequency, gradually increased to 30Hz (intensity between 25-35µT). The primary outcome was fatigue, assessed with the Fatigue Severity Scale (FSS) and the Modified Fatigue Impact Scale (MFIS). Secondary measures included walking function (GAITRite system and Timed 25-Foot Walk test), the Beck Depression Inventory-II, and the Multiple Sclerosis International Quality of Life Questionnaire. Data were collected at baseline, after intervention, and at 3-months post-intervention (follow-up). There were no differences between groups for changes in fatigue symptoms from baseline to end of intervention (mean and 95% confidence interval FSS: -0.6, 95%CI: -1.3, 0.1; MFIS: -5.4, 95% CI: -15.1, 4.4) or at follow-up (FSS: -0.6, 95% CI: -1.4, 0.2; MFIS: -2.1, 95% CI: -10.9, 6.8). Similarly, both groups did not differ for any of the secondary outcomes at post-intervention or follow-up. Low-frequency PEMF therapy is no more effective than placebo to produce changes in fatigue, gait performance, severity of depression, and QOL in people with RRMS and minimal to significant disability.enAttribution-NonCommercial-NoDerivatives 4.0 Internationalhttp://creativecommons.org/licenses/by-nc-nd/4.0/FatigueMagnetic field therapyNeurologic gait disordersPlacebo effectQuality of lifeRelapsing-remitting multiple sclerosisAdultHumansQuality of LifeMultiple SclerosisElectromagnetic FieldsDepressionFatigueWalkingMultiple Sclerosis, Relapsing-Remittingresearch article36283240open access10.1016/j.bjpt.2022.1004491809-9246PMC9594115https://doi.org/10.1016/j.bjpt.2022.100449https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9594115/pdf